Uptown Research Institute Logo Banner

Schizophrenia and Weight Gain: Outpatient

Purpose of this Study: Zyprexa (olanzapine), an effective treatment for schizophrenia, causes significant weight gain among some users. This study examines if pairing Zyprexa with Samidorphan, an experimental medication, can prevent weight gain associated with Zyprexa.

Learn more and Sign Up for this Study

Design of Study: All study participants receive Zyprexa. In addition to Zyprexa, half of the participants also receive Samidorphan and the other half receive a placebo instead of Samidorphan. You will be monitored for general safety, control of schizophrenia, safety, and weight.

Length of Study: Twenty (20) visits over 30 weeks.

Qualified Study Participants Will Receive:

  • Study-related care and office visits at no cost
  • Investigational study medication at no cost
  • $75 compensation per visit

Am I Eligible for the Study?

  • Aged 18 - 55 years old
  • Diagnosed with schizophrenia
  • Medically stable with a stable living residence
Note: These are not the only eligibility criteria for this clinical research study, and other criteria may exclude you.

Why Should You Participate? Clinical trials are how all new medicines are tested. These trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. You may also help others by advancing science.

Interested in Participating? If you are interested in joining this study, please fill out the form below to provide your contact information, or call our office at (773) 989-8313 x 2 and leave a message on our screening line. A member of our staff will call you back within 24 hours and will conduct a short phone screen to determine if you should visit our office for further evaluation.

Studies Form
Please write or copy and paste the study name listed above here.
Please let us know any additional information here.
Sending

Treatment Resistant Schizophrenia: Outpatient

Purpose of this Study: This study examines if the new study medication is safe and effective in treating schizophrenia in patients that are experiencing continued symptoms of psychosis even though they take medication.

Learn more and Sign Up for this Study

Design of Study: This is an outpatient study. Participants will receive either Zyprexa or Risperdal for the first part of the study. If they fully respond to one of these medications, their participation ends and they do not receive the study drug. If they do not fully respond they are assigned to take the new study drug or to stay on the Zyprexa or Risperdal. At the study’s completion, participants have the option to take the study medication for one year.

Length of Study: Fourteen (14) visits over 22 weeks.

Qualified Study Participants Will Receive:

  • Study-related care, inpatient care, and office visits at no cost
  • Investigational study medication at no cost
  • $75 compensation per visit

Am I Eligible for the Study?

  • Aged 18 or over
  • Diagnosed with Schizophrenia
  • Have an identified caregiver or family member
  • Medically stable with a stable living residence
Note: These are not the only eligibility criteria for this clinical research study, and other criteria may exclude you.

Why Should You Participate? All new medicines are tested in clinical trials. You may also help others by advancing science, and you may gain access to a new treatment.

Interested in Participating? If you are interested in joining this study, please fill out the form below to provide your contact information, or call our office at (773) 989-8313 x 2 and leave a message on our screening line. A member of our staff will call you back within 24 hours and will conduct a short phone screen to determine if you should visit our office for further evaluation.

Studies Form
Please write or copy and paste the study name listed above here.
Please let us know any additional information here.
Sending

Bipolar Mania: Inpatient

Purpose of this Study: This study examines if Brexpiprazole is safe and effective in treating manic episodes that occur with Bipolar 1 Disorder. The study medicine is approved for use in schizophrenia, prescribed as Resulti.

Learn more and Sign Up for this Study

Design of Study: This is an inpatient study. Participants are required to remain in the hospital for 3-4 weeks and must agree to stopf current medications used to treat their Bipolar Disorder. Participants will receive Brexpiprazole or a placebo.

Length of Study: Approximately 8 weeks. (including a 3-4 week inpatient hospital stay).

Qualified Study Participants Will Receive:

  • Study-related care, inpatient care, and office visits at no cost
  • Investigational study medication at no cost
  • $75 compensation per visit

Am I Eligible for the Study?

  • Aged 18 - 65 years old
  • Diagnosed with Bipolar 1 and experiencing an acute manic episode
  • History of at least one prior manic episode that required intervention or hospitalization
  • Medically stable with a stable living residence
Note: These are not the only eligibility criteria for this clinical research study, and other criteria may exclude you.

Why Should You Participate? All new medicines are tested in clinical trials. You may also help others by advancing science, and you may gain access to a new treatment.

Interested in Participating? If you are interested in joining this study, please fill out the form below to provide your contact information, or call our office at (773) 989-8313 x 2 and leave a message on our screening line. A member of our staff will call you back within 24 hours and will conduct a short phone screen to determine if you should visit our office for further evaluation.

Studies Form
Please write or copy and paste the study name listed above here.
Please let us know any additional information here.
Sending

Bipolar Depression: Outpatient

Purpose of this Study: This study examines if a new medication is safe and effective in treating patients with Bipolar disorder who are currently depressed.

Learn more and Sign Up for this Study

Design of Study: This is an outpatient study and all participants will receive either the study medication or a placebo. Participants on Depakote or Lithium may stay on these medications throughout the study.

Length of Study: Nine (9) visits over 10 weeks.

Qualified Study Participants Will Receive:

  • Study-related care and office visits at no cost
  • Medication at no cost
  • $75 compensation per visit

Am I Eligible for the Study?

  • Aged 18 - 65 years old
  • Diagnosis of Bipolar Disorder
  • Current depressive episode lasting from 2 weeks to 6 months
  • Medically stable with a stable living residence
Note: These are not the only eligibility criteria for this clinical research study, and other criteria may exclude you.

Why Should You Participate? Clinical trials are how all new medicines are tested. These trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. You may also help others by advancing science and may gain access to a new treatment.

Interested in Participating? If you are interested in joining this study, please fill out the form below to provide your contact information, or call our office at (773) 989-8313 x 2 and leave a message on our screening line. A member of our staff will call you back within 24 hours and will conduct a short phone screen to determine if you should visit our office for further evaluation.

Studies Form
Please write or copy and paste the study name listed above here.
Please let us know any additional information here.
Sending

Post Traumatic Stress Disorder - Military Related: Outpatient

Purpose of this Study: This study examines the safety and effectiveness of the study drug, cyclobenzaprine, for the management of patients with military-related post-traumatic stress disorder (PTSD).

Learn more and Sign Up for this Study

Design of Study: This is an outpatient study open to individuals with military-related PTSD. Subjects will receive either the study medication or a placebo (“sugar pill”). At the end of the study, all participants have the option to continue on the active study medication.

Length of Study: 12 Weeks; with an option to rollover into a treatment only study at the end.

Qualified Study Participants Will Receive:

  • Study-related care and office visits at no cost
  • Medication at no cost
  • $75 compensation per visit

Am I Eligible for the Study?

  • Aged 18 - 75 years old
  • A diagnosis of military-related PTSD, and can show proof of service since 2001
  • Willing and able to withdraw from prohibited medications for the duration of the study
  • Medically stable with a stable living residence
Note: These are not the only eligibility criteria for this clinical research study, and other criteria may exclude you.

Why Should You Participate? This study offers state-of-the-art care tailored to adults with military-related PTSD at no cost to the participant. You may also help others by advancing science.

Interested in Participating? If you are interested in joining this study, please fill out the form below to provide your contact information, or call our office at (773) 989-8313 x 2 and leave a message on our screening line. A member of our staff will call you back within 24 hours and will conduct a short phone screen to determine if you should visit our office for further evaluation.

Studies Form
Please write or copy and paste the study name listed above here.
Please let us know any additional information here.
Sending

Early Intervention for Schizophrenia: Outpatient

Purpose of this Study: This study examines early intervention as a means to achieve optimal functioning and symptom control in patients with Schizophrenia.

Learn more and Sign Up for this Study

Design of Study: This is an outpatient study and all participants will be on commercially available branded medication for the study duration. Participants start on Invega pills and have a chance of receiving the injectable Invega Sustenna. They may be changed to other approved medications as clinically needed. In addition to assessing symptoms of psychosis, the study examines functional outcomes, such as the use of medical resources and involvement in school and work. All participants require an identified “informant,” such as a caregiver or family member, who can report on their well-being.

Length of Study: Approximately 50 visits over two years.

Qualified Study Participants Will Receive:

  • Study-related care and office visits at no cost
  • Medication at no cost
  • Patient and “informant”will each receive $75 compensation per visit

Am I Eligible for the Study?

  • Aged 18 - 35 years old
  • First psychotic episode within two years of study entry
  • Have an identified caregiver or family member
  • Medically stable with a stable living residence
Note: These are not the only eligibility criteria for this clinical research study, and other criteria may exclude you.

Why Should You Participate? This study offers state-of-the-art care tailored to young adults with a recent onset of symptoms. You may also help others by advancing science.

Interested in Participating? If you are interested in joining this study, please fill out the form below to provide your contact information, or call our office at (773) 989-8313 x 2 and leave a message on our screening line. A member of our staff will call you back within 24 hours and will conduct a short phone screen to determine if you should visit our office for further evaluation.

Studies Form
Please write or copy and paste the study name listed above here.
Please let us know any additional information here.
Sending